Once a diabetes drug, now the center of gravity in a category reshaping pharmacy, telehealth, and the business of long-term obesity care. When the first generation of GLP-1 receptor agonists began moving from endocrinology clinics into mainstream weight management, analysts called it an inflection point. Few predicted how sharp the curve would become. By 2026, [...] The post The Second Act of GLP-1: How Tirzepatide Rewrote the Economics of Medical Weight Loss appeared first on TechBullion .
The Second Act of GLP-1: How Tirzepatide Rewrote the Economics of Medical Weight Loss
